20:58 , Oct 13, 2017 |  BioCentury  |  Finance

Sprucely debut

Spruce Biosciences Inc. emerged from stealth mode on Oct. 12, unveiling a $20 million series A round the company says will fund an ongoing Phase II study for a rare endocrine indication and could propel...
19:53 , Oct 13, 2017 |  BC Week In Review  |  Financial News

Rare endocrine play Spruce emerges from stealth and announces $20M series A

On Oct. 12, Spruce Biosciences Inc. (San Francisco, Calif.) revealed a $20 million series A round of funding and said it has begun enrolling patients in a U.S. Phase II trial of its lead program,...
14:20 , Oct 12, 2017 |  BC Extra  |  Financial News

Rare endocrine play Spruce emerges from stealth

Spruce Biosciences Inc. (San Francisco, Calif.) revealed a $20 million series A round of funding and said it has begun enrolling patients in a U.S. Phase II trial of its lead program, SPR001 , to...